Regional Dermatology Practices Are Quietly Selling to PE Rollups

The Quiet Consolidation of American Dermatology

Private equity has been buying up dermatology practices for years, but the pace has accelerated – and the targets have shifted. It is no longer just large urban group practices drawing acquisition interest. Solo practitioners and small regional clinics in mid-size markets are now fielding serious offers, often from rollup platforms they have never heard of.

Why Dermatology Became PE’s Favorite Medical Specialty

Dermatology checks nearly every box private equity firms look for in a healthcare rollup. The specialty generates predictable, recurring revenue through a mix of medical and cosmetic procedures. Overhead is manageable compared to surgical specialties. Reimbursement rates are relatively stable, and the cosmetic side of the business – Botox, fillers, laser treatments – is largely cash-pay, meaning no insurance negotiations, no claims processing delays, and no capitation risk. That combination of clinical revenue and elective cash procedures is exceptionally attractive from a margin standpoint.

The demographics also work in PE’s favor. An aging population drives steady demand for skin cancer screenings, acne treatment, rosacea management, and cosmetic correction. At the same time, there is a documented shortage of practicing dermatologists in non-metropolitan areas, which means regional practices often carry more patient volume than they can comfortably manage. A PE-backed platform can argue, credibly, that it is solving an access problem while simultaneously extracting margin.

The consolidation math is straightforward. A solo dermatologist running a practice with strong EBITDA might sell at a multiple that reflects their size and market position. That same practice, once folded into a larger platform with dozens of locations, gets revalued at a significantly higher multiple when the platform itself goes to market. The rollup model captures the difference between those two valuations – called multiple arbitrage – and that spread funds the entire acquisition strategy. Dermatology’s fragmented structure, with thousands of independent practices across the country, makes it an ideal environment for this approach.

This pattern is not unique to medicine. Regional dental practices have followed a nearly identical trajectory, with DSO platforms buying independent offices and consolidating them under centralized management structures. Dermatology is running the same playbook, just a few years behind.

What Selling Physicians Are Actually Being Offered – and What They Are Giving Up

The pitch to a practice owner typically arrives through a broker or directly from a platform’s acquisition team, and it leads with a number that is hard to ignore. Dermatology practices with strong revenue and clean financials are reportedly selling at multiples that would have seemed implausible a decade ago. For a physician who has spent fifteen or twenty years building a patient base, that kind of liquidity event represents generational wealth – often more than they could accumulate through decades of additional clinical practice.

The structure of these deals usually involves the physician receiving a portion of the purchase price upfront, with another portion tied to equity in the platform. That equity component is where PE firms align physician incentives with the rollup’s growth targets. If the platform performs well and eventually sells to a larger buyer or takes on new capital, the physician’s retained equity could pay out again. That second bite of the apple is a recurring theme in acquisition pitches, and it is genuinely real – when deals work as planned.

What changes after the sale is harder to quantify in a term sheet. Most transactions include a management services agreement that shifts administrative control to the platform while the physician retains nominal clinical autonomy. In practice, this means staffing decisions, billing systems, vendor contracts, and scheduling protocols move to the platform’s centralized operations team. Physicians who were accustomed to running their own practices as they saw fit often find the adjustment jarring. Compensation structures may also change, with productivity benchmarks that were not part of the original employment agreement starting to appear in subsequent contract cycles.

Patient experience is a harder variable to track, but the concern is real. Regional practices often retain patients because of personal relationships with physicians and staff. When ownership changes and administrative priorities shift toward throughput and margin, that relational quality can erode. Staff turnover tends to accelerate after acquisitions, and appointment availability – paradoxically – can actually worsen in the near term as the new platform works through operational integration.

There is also the question of what happens when the platform itself sells. PE funds operate on defined timelines, typically five to seven years. When a fund reaches the end of its investment cycle, the platform goes to market again – sold to a larger strategic buyer, another PE firm, or taken public. The physician’s equity situation at that point depends entirely on how the platform’s value held up, how much debt was loaded onto the business during the holding period, and what the exit conditions look like. Those variables are largely outside any individual physician’s control once they have signed.

What Comes Next for Independent Practices That Have Not Sold

Independent dermatologists who have resisted acquisition offers are now navigating a market where their competitors may have access to larger marketing budgets, centralized billing operations, and negotiating leverage with suppliers. Some are responding by forming physician-owned groups that can achieve scale without PE involvement – pooling administrative resources, negotiating contracts collectively, and expanding to additional locations on their own capital. That path requires a different kind of work and a different kind of risk tolerance than private practice ownership, but it exists.

The harder question is whether the window for independent practice is closing structurally, or whether the PE rollup wave will crest and recede the way consolidation cycles sometimes do in other industries. Some PE-backed dermatology platforms are already carrying significant debt loads, and rising interest rates have made the arbitrage math less automatic than it was three years ago. If a major platform runs into refinancing trouble or fails to achieve its projected exit multiple, the fallout for the physicians who took equity in that platform – rather than full cash at closing – could be substantial.